Literature DB >> 8378032

Study of the pharmacokinetics of mitomycin C in humans during intraperitoneal chemohyperthermia with special mention of the concentration in local tissues.

G Panteix1, M Guillaumont, L Cherpin, J Cuichard, F N Gilly, P Y Carry, A Sayag, B Salle, A Brachet, J Bienvenu.   

Abstract

The aim of this work is to estimate the 24-hour distribution and elimination of mitomycin C (MMC) during and after intraperitoneal chemohyperthermia (IPCH) in 18 patients (13 gastric adenocarcinoma, 3 pancreatic adenocarcinoma, 2 malignant mesothelioma) who received 60 mg MMC during 90-120 min in 6 liters of heating solution HS; (42 degrees C) or HS flowing at 0.4 liters/min in a closed circuit. MMC assay in the serum, urine, HS and in local biopsies were performed by high performance liquid chromatography. The amount of MMC in HS decreased by 54.1 +/- 13.6% during IPCH. The maximum MMC levels in serum reached 0.4 +/- 0.18 mg/l 45 min after the start of IPCH, then rapidly decreased. Only 1.77 +/- 0.93 mg were recovered in urine in 24 h. These data are consistent with a large and rapid absorption, mostly in local tissue, demonstrated by the level in 7 post-IPCH biopsies (8.3 +/- 7.6 mg/kg).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8378032     DOI: 10.1159/000227211

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  10 in total

1.  Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC).

Authors:  Rong-Xin Zhang; Jun-Zhong Lin; Jian Lei; Gong Chen; Li-Ren Li; Zhen-Hai Lu; Pei-Rong Ding; Jiong-Qiang Huang; Ling-Heng Kong; Fu-Long Wang; Cong Li; Wu Jiang; Chuan-Feng Ke; Wen-Hao Zhou; Wen-Hua Fan; Qing Liu; De-Sen Wan; Xiao-Jun Wu; Zhi-Zhong Pan
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-28       Impact factor: 4.553

2.  Hyperthermic intraperitoneal chemotherapy: Rationale and technique.

Authors:  Santiago González-Moreno; Luis A González-Bayón; Gloria Ortega-Pérez
Journal:  World J Gastrointest Oncol       Date:  2010-02-15

Review 3.  Management of pseudomyxoma peritonei.

Authors:  Zhi-Bo Qu; Lian-Xin Liu
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

4.  Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.

Authors:  Serge van Ruth; Ron A A Mathôt; Rolf W Sparidans; Jos H Beijnen; Vic J Verwaal; Frans A N Zoetmulder
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer.

Authors:  Y Yonemura; I Ninomiya; M Kaji; K Sugiyama; K Fujimura; T Sawa; K Katayama; S Tanaka; Y Hirono; K Miwa
Journal:  World J Surg       Date:  1995 May-Jun       Impact factor: 3.352

Review 6.  Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: a systematic review.

Authors:  D A M Sloothaak; B Mirck; C J A Punt; W A Bemelman; J D W van der Bilt; A D'Hoore; P J Tanis
Journal:  Br J Cancer       Date:  2014-07-15       Impact factor: 7.640

Review 7.  Principles and Innovations in Peritoneal Surface Malignancy Treatment.

Authors:  Kelly M MacArthur; Michael B Nicholl
Journal:  World J Oncol       Date:  2013-07-15

8.  Peritoneal mesothelioma in Sweden: A population-based study.

Authors:  Peter H Cashin; Gabriella Jansson Palmer; Dan Asplund; Wilhelm Graf; Ingvar Syk
Journal:  Cancer Med       Date:  2019-09-04       Impact factor: 4.452

9.  Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in colorectal carcinoma at high risk of peritoneal carcinomatosis: short-term and long-term outcomes from the CHECK study - protocol for a randomised, multicentre, phase 3 trial.

Authors:  Fabio Pacelli; Chiara Gerardi; Eliana Rulli; Carlo Abatini; Stefano Rotolo; Silvio Garattini; Gianluigi Melotti; Valter Torri; Fabio Galli; Erica Rulli; Andrea Di Giorgio
Journal:  BMJ Open       Date:  2022-08-01       Impact factor: 3.006

Review 10.  Intracavitary therapies for mesothelioma.

Authors:  C F Verschraegen
Journal:  Curr Treat Options Oncol       Date:  2001-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.